← back to search

Grant Theron

University of Cape Town · ZA
Area of research
Infectious Diseases · Epidemiology
Research interest
Research focused on Tuberculosis and Extensively drug-resistant tuberculosis, with related work in Sputum, Intensive care medicine, Bedaquiline. Notable publications include 'The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis', 'Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial', and 'Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis'.
h-index
citations
3,603
works
36
NIH funding
primary concept
email

Recent publications

Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis
PLoS Medicine 2025cited by 7position: middledoi
Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future research
The Lancet Global Health 2024cited by 61position: middledoi
Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa
The Lancet Global Health 2024cited by 38position: middledoi
Blood RNA biomarkers for tuberculosis screening in people living with HIV before antiretroviral therapy initiation: a diagnostic accuracy study
The Lancet Global Health 2024cited by 20position: middledoi
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
Clinical Infectious Diseases 2024cited by 13position: middledoi
A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosis
The Lancet Global Health 2024cited by 12position: middledoi
In-home TB Testing Using GeneXpert Edge is Acceptable, Feasible, and Improves the Proportion of Symptomatic Household Contacts Tested for TB: A Proof-of-Concept Study
Open Forum Infectious Diseases 2024cited by 9position: lastdoi
Critical assessment of infants born to mothers with drug resistant tuberculosis
EClinicalMedicine 2024cited by 2position: middledoi
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study
The Lancet Microbe 2023cited by 99position: lastdoi
Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data
The Lancet Global Health 2023cited by 85position: middledoi
Genome-wide tiled detection of circulating Mycobacterium tuberculosis cell-free DNA using Cas13
Nature Communications 2023cited by 45position: middledoi
Clinical utility of WHO-recommended screening tools and development and validation of novel clinical prediction models for pulmonary tuberculosis screening among outpatients living with HIV: an individual participant data meta-analysis
European Respiratory Review 2023cited by 10position: middledoi
Mycobacterium tuberculosis Transmission in High-Incidence Settings—New Paradigms and Insights
Pathogens 2022cited by 77position: middledoi
Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis
EBioMedicine 2021cited by 53position: lastdoi
Development and clinical evaluation of a new multiplex PCR assay for a simultaneous diagnosis of tuberculous and nontuberculous mycobacteria
EBioMedicine 2021cited by 20position: middledoi
Health care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, Zimbabwe: A prospective cohort study
PLoS ONE 2021cited by 11position: middledoi
The child ecosystem and childhood pulmonary tuberculosis: A South African perspective
Pediatric Pulmonology 2021cited by 2position: middledoi
Systematic review of mutations associated with resistance to the new and repurposed<i>Mycobacterium tuberculosis</i>drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid
Journal of Antimicrobial Chemotherapy 2020cited by 205position: middledoi
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis
Nature Medicine 2020cited by 75position: firstdoi
The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda
The Lancet Respiratory Medicine 2019cited by 135position: lastdoi
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
The Lancet Respiratory Medicine 2019cited by 118position: middledoi
Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis
The Lancet Global Health 2019cited by 73position: middledoi
Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
New England Journal of Medicine 2019cited by 73position: middledoi
Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation
The Lancet Global Health 2019cited by 52position: middledoi
Point of care diagnostics for tuberculosis
Pulmonology 2018cited by 125position: lastdoi
Evaluation of the airway microbiome in nontuberculous mycobacteria disease
European Respiratory Journal 2018cited by 115position: middledoi
The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates<i>Mycobacterium tuberculosis–</i>Specific Host Immunity Through the Glucocorticoid Receptor
The Journal of Infectious Diseases 2018cited by 8position: middledoi
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
The Lancet Respiratory Medicine 2017cited by 673position: middledoi
Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study
The Lancet Respiratory Medicine 2017cited by 132position: middledoi
Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance
Antimicrobial Agents and Chemotherapy 2017cited by 63position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Keertan Dheda · London School of Hygiene & Tropical Medicine13 papers (2013–2025)Robin M. Warren · London School of Hygiene & Tropical Medicine8 papers (2014–2023)John Metcalfe · San Francisco General Hospital6 papers (2017–2023)David W. Dowdy · Sydney Local Health District5 papers (2013–2024)Jonny Peter · University of Cape Town4 papers (2013–2019)Byron W P Reeve · University of Cape Town4 papers (2021–2025)Lucas Smith · University of Cape Town4 papers (2014–2020)Jason Limberis · San Francisco General Hospital4 papers (2017–2023)Anete Trajman · McGill University Health Centre3 papers (2019–2025) · 3 papers (2013–2019)Mark P. Nicol · The University of Western Australia3 papers (2019–2024)Benjamin G. Wu · Veterans Health Administration3 papers (2018–2021)Tania Dolby · Boston Medical Center3 papers (2017–2023)C Naidoo · Westmead Hospital3 papers (2018–2021)Aliasgar Esmail · University of Cape Town3 papers (2017–2025)Leopoldo N. Segal · New York University3 papers (2018–2021) · 3 papers (2013–2019)Mahdad Noursadeghi · University College London Hospitals NHS Foundation Trust3 papers (2021–2024)Claudia M. Denkinger · Heidelberg University3 papers (2017–2024)Duncan Chanda · London School of Hygiene & Tropical Medicine3 papers (2013–2019)